Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
When you work with our Custom Intelligence and Pharma Consulting Team, you draw on the strength of the entire Pharma Intelligence family. That means best-in-class data sets, over 400 industry-leading experts, and years of experience in delivering projects tailored to your specific needs and strategy.
That means over 400 global pharma and medtech industry-leading experts, including experts on APAC and emerging markets, years of experience in delivering projects tailored to your specific needs, and the trusted data of the entire suite of Pharma Intelligence industry intelligence solutions.
The result: personalized advice and rock-solid data to help fully inform your next critical decision.
Our team of consultants have backgrounds in pharma, biotech, and medical device R&D; business intelligence and market analysis; brand management, marketing strategy & launch planning; market research, regulatory affairs and business development and licensing.
Maximize opportunities, navigate uncertainties, and ensure more successful outcomes
Staying ahead of the competition is difficult. Pharma and biotech decision makers trust Custom Intelligence for an independent view of the market to maximize opportunities, to avoid risk and ensure more successful outcomes.
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q2 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q1 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q4 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
This Q3 2021 report introduces two new gene therapies in the European (EU) and China, 323 gene therapies in preclinical development, and the on-going progress of gene therapies for rare diseases and non-oncology indications.
Most recently, attention in cancer immunotherapy has shifted to neoantigen-based immunotherapies – immunotherapies which target neoantigens, patient-specific peptides found on the surface of tumor cells. These highly personalized immunotherapies promise to unleash the natural power of a patient’s immune system to recognize an individual patient’s tumor antigens and to destroy cancer cells.
If there is one fact that even the most casual observer of the pharma industry is aware of, it is that biologics are the leading growth engine of global medicines spending. Revenues from biologics increased by 70% during 2011–16 to reach $232bn, accounting for roughly 20–22% of total pharmaceutical spending.
Gene editing is positioning itself as the latest evolution of genetic therapies and is due for an inflection point in 2022 as a number of milestones will be reached.
Pompe disease is an extremely rare disorder in Japan, making the task of assessing epidemiology, diagnosis, and understanding patient needs complex.
The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward.
Duncan Specialises in
23+ years of experience
Ly Specialises in
22+ years of experience
Daniel Specialises in
13+ years of experience
Shardha Specialises in
How can we help you?
Contact us at:
customintelligence@informa.com
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
